# Expanded Access to Rovalpituzumab Tesirine

> **NCT03503890** · — · NO_LONGER_AVAILABLE · sponsor: **AbbVie**

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** rovalpituzumab tesirine

## Key facts

- **NCT ID:** NCT03503890
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2019-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03503890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03503890, "Expanded Access to Rovalpituzumab Tesirine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03503890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*